1 Missed opportunities of flu vaccination in Italian

2 target categories: insights from the online EPICOVID

з 19 survey

- 4 Andrea Giacomelli*1, Massimo Galli*1, Stefania Maggi², Gabriele Pagani¹, Raffaele Antonelli
- 5 Incalzi³, Claudio Pedone³, Mauro di Bari⁴, Marianna Noale², Caterina Trevisan^{2,5}, Fabrizio
- 6 Bianchi⁶, Marcello Tavio⁷, Massimo Andreoni⁸, Claudio Mastroianni⁹, Aleksandra Sojic¹⁰,
- 7 Federica Prinelli¹⁰ and Fulvio Adorni¹⁰ on Behalf of EPICOVID19 Working Group.
- 8 ¹Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di
- 9 Milano, ASST Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy;
- 10 <u>andrea.giacomelli@unimi.it; massimo.galli@unimi.it; gabriele.pagani@unimi.it</u>
- 11 ²National Research Council, Institute of Neuroscience, Aging branch, Via Vincenzo Maria Gallucci
- 12 16, 35128 Padova; stefania.maggi@in.cnr.it; caterina.trevisan.5@studenti.unipd.it;
- 13 marianna.noale@in.cnr.it
- 14 ³Unit of Geriatrics, Department of Medicine, Biomedical Campus of Rome, via Alvaro del Portillo,
- 21, 00128 Rome, Italy; <u>r.antonelli@unicampus.it</u>; <u>claudio.pedone@gmail.com</u>
- 16 Geriatric Intensive Care Medicine, University of Florence and Azienda Ospedaliero-Universitaria
- 17 Careggi, Viale Peraccini 18, 50139 Florence, Italy; mauro.dibari@unifi.it
- 18 ⁵Geriatric Unit, Department of Medicine (DIMED), University of Padova, Via Giustiniani 2, 35128
- 19 Padova, Italy; <u>caterina.trevisan.5@studenti.unipd.it</u>
- 20 6 National Research Council, Institute of Clinical Physiology, Via G. Moruzzi 1, 56124 Pisa (PI),
- 21 Italy; fabriepi@ifc.cnr.it
- 22 ⁷Division of Infectious Diseases, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona,
- 23 Italy; <u>marcello.tavio@ospedaliriuniti.marche.it</u>
- 24 8Infectious Diseases Clinic, Department of System Medicine, Tor Vergata University of Rome,
- 25 00133 Rome, Italy; andreoni@uniroma2.it
- ⁹Public Health and Infectious Disease Department, "Sapienza" University, Rome, Italy;
- 27 <u>claudio.mastroianni@uniroma1.it</u>
- 28 ¹⁰National Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090
- 29 Segrate (MI), Italy; aleksandra.sojic@itb.cnr.it; federica.prinelli@itb.cnr.it;
- 30 <u>fulvio.adorni@itb.cnr.it;</u>

31

33 34

35

36

37

38

32 *The authors contributed equally to the manuscript

Vaccines 2020, 8, x; doi: FOR PEER REVIEW

2 of 15

Vaccines 2020, 8, x FOR PEER REVIEW

39 40 41 Corresponding author: 42 Andrea Giacomelli, MD 43 Luigi Sacco DIBIC, University of Milan, 44 III Infectious Diseases Unit, L. Sacco Hospital, 45 Via G.B. Grassi 74, 20157 Milano, 46 47 Italy 48 Tel. +39.02.50319761; Fax +39.02.50319758; E-mail andrea.giacomelli@unimi.it ORCID ID: 0000-0003-3685-4289 49 50 51 52 53 Abstract: We aimed to assess the reported rate of flu vaccination in the season 2019/2020 in 54 respondents to the Italian nationwide online EPICOVID 19 survey. A national convenience sample of volunteers aged 18 or older was assessed between 13th April and 2nd June 2020. Flu vaccine rates 55 were calculated for all classes of age. The association between the independent variables and the flu 56 57 vaccine was assessed by applying a multivariable binary logistic regression model. Of the 198,822 58 respondents 41,818 (21.0%) reported to have received a flu vaccination shot during the last 59 influenza season. In particular, 15,009 (53.4%) subjects aged 65 years or older received a flu 60 vaccination shot. Being 65 years aged or older (aOR 3.06, 95%CI 2.92-3.20) and having a high 61 education level (aOR 1.34. 95%CI 1.28-1.41) were independently associated to flu vaccination. Heart 62 and lung diseases were the morbidities associated with the higher odds of being vaccinated [aOR 63 1.97 (95%CI 1.86-2.09) and aOR 1.92 (95%CI 1.84-2.01), respectively]. Nursing home residents aged 64 ≥ 65 years showed a lower odds of being vaccinated [aOR 0.39 (95%CI 0.28-0.54)]. Our data claims 65 for an urgent public heath effort to fill the gap of missed vaccination opportunities reported in the 66 past flu seasons. 67 68 **Keywords:** SARS-CoV-2, COVID-19, influenza, vaccine, elderly, Italy 69 70 71 72 73 74

Vaccines 2020, 8, x FOR PEER REVIEW

1. Introduction

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

117

118

Influenza is an acute viral infection of the respiratory tract, whose clinical manifestations range from mild upper respiratory tract symptoms to life treating complications requiring hospitalization. It is estimated that every year flu can cause worldwide high morbidity and mortality epidemics with approximately 3 to 5 million cases and between 250,000 and 500,000 deaths [1]. In the northern hemisphere Influenza viruses circulating during fall and winter seasons cause epidemic outbreaks with an important burden of morbidity and a remarkable mortality rate. In Italy, the cost for the national health care system has been estimated an average of 1.4 US\$ billion for each season between

1999 and 2008 [2].

The new pandemic caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) has rapidly spread starting from China in late December 2019 and abruptly involving the north of Italy in late February 2020 [3]. SARS-CoV-2 infection is able to cause a severe respiratory syndrome with the requirement of intensive care assistance and eventually leading to death in a significant percentage of hospitalized patients [4, 5]. The dramatic impact of the SARS-CoV-2 pandemic on the Italian national healthcare system lead the national authorities to impose a national lock-down from March 9 to May 18, 2020. After a period of apparent control in summer months, current Italian epidemiological situation is evolving with a slight daily increment of the number of cases and a progressive increment of hospitalized patients [6]. Consequently, non-pharmacological interventions, such as the face mask combined with social distancing, are still enforced.

The new challenge in the management of the pandemic will appear in the 2020/2021 flu season, when the co-occurrence of influenza and flu-like illnesses may overcome the diagnostic capacity of our system with regard to the capability for molecularly testing all subjects with respiratory symptoms. Moreover, the clinical impact of subsequent or concomitant influenza and SARS-CoV-2 infections is still unknown, especially in the elderly populations and in patients with comorbidities.

To date, no effective treatment has been demonstrated to radically change the natural history of SARS-CoV-2 infection [7] and several vaccination strategies are still under development [8]; on the other hand, flu vaccination is able to decrease both the incidence rates of influenza and to moderate the severity of the disease in case of infection. Moreover, a remarkable decrease in morbidity for pneumonia, respiratory and cardiovascular complications and consequent risk of hospitalization and death has been consistently reported in the literature [9-12]. The reduced risk of hospitalization is particularly important considering the significant amount of hospital resources that are required for the management of COVID 19 patients which required hospitalization and intensive care assistance in a not negligible percentage [4, 5]. In the end, influenza vaccinations are not only safe, with few adverse events related to its administration, but also proven to be effective in children above 6 months of age, people with comorbid conditions and also in the elderly population [9, 10, 13].

112 Despite national and international recommendations for routine flu vaccination, vaccine uptake in 113 Italy remains low in the general population, as well as in the high risk groups. Our aim was to 114 assess the reported rate of flu vaccination in the season 2019/2020 in respondents to the nationwide 115 online EPICOVID 19 survey [14] and to identify factors associated with the uptake of flu vaccination,

116 in order to address potential gaps to be filled in the public health system.

2. Materials and Methods

2.1 Study design and setting

Vaccines 2020, 8, x FOR PEER REVIEW

4 of 15

- 119 The study design was described elsewhere [14, 15] and the study was registered (ClinicalTrials.gov
- 120 NCT04471701). In brief, EPICOVID19 is an Italian cross-sectional, web-based survey that was
- initiated in April 2020. A national convenience sample of volunteers aged 18 or older with access to
- internet and able to give an informed consent was assessed. The participants were recruited via
- social media (Facebook, Twitter, Instagram, Whatsapp), press releases, internet pages, local radio,
- 124 TV stations, and institutional websites; the European Commission's open-source official EUSurvey
- management tool was used to collect the data (https://epicovid19.itb.cnr.it/). The geographical
- 126 coverage [14] such as the representativeness of the survey according to the Italian official
- demographic data [15] were described elsewhere.

2.2 Data collection and variables

- 129 For the purposes of this study, we analysed all the survey responses collected between 13th April
- and 2nd June 2020. The socio-demographic information included sex (male vs female, furtherly
- classified as pregnant or not), age (18-24, 25-29 up to 90+ and further categorized as <65 or ≥ 65 years
- of age), educational level (primary school or less = Low, middle or high school = Medium, and
- university degree or post-graduate = High), and occupational status (unemployed, employed,
- retired, student, and other). Work categories included in the national guidelines for flu vaccine were
- 135 generated (Health professionals, armed forces, agricultural, forestry and fisher workers). Two ad
- 136 hoc dummy variables were also created for categorizing residents in nursing homes (yes or not) and
- for respondents living with an "at risk cohabitant" according to the 2017-2019 Italian national
- vaccination plan (yes or not) [16]. Chronic conditions reported were lung diseases, heart diseases,
- metabolic disorders, renal diseases, oncological diseases, diseases of the immune system, liver diseases and pre-planned major surgical procedures. A new variable was created by summing the
- diseases and pre-planned major surgical procedures. A new variable was created by summing the chronic conditions referred by participants (categorised as none, 1, 2 or ≥3 co-morbidities).
- 142 Information about autonomy in carrying out daily activities, self-rated health (very bad, bad,
- 143 adequate, good or very good) was also available. The participants were also asked if they had
- received an influenza vaccination during the previous autumn/winter season.

145 2.3 Study population and group definition

- Out of the 207,341 respondents, the study population consisted of 198,822 participants who provided
- informed consent, and for whom the data were fully available for the analysis. For the aim of this
- study, participants were categorized as vaccinated or not vaccinated for flu during the 2019/2020
- 149 season.

150

163

128

2.4 Statistical analysis

- 151 Descriptive analyses were performed to show the numerical distributions, overall and by flu vaccine
- status, of all the variables that at a later stage were included as independent in the models applied
- for statistical inference. Continuous variables were expressed as mean [Standard Deviation (SD)]
- whereas categorical and ordinal ones as count and percentages. Flu vaccine rates were calculated for
- all classes of age and for all Italian regions, in this latter case also stratifying by sex (male vs female)
- and age (<65 vs ≥65 years). The association between the independent variables and the flu vaccine
- 157 (0=not reported, 1=reported) was assessed by applying a multivariable binary logistic regression
- 158 model. Adjusted Odds Ratios (aOR), together with their 95% Confidence Intervals (CI), were
- estimated for each independent variable, with p-level of statistical significance set at .05, two tails.
- The same regression model was used when restricting the population analysed to older people (≥65
- years). All the statistical analyses were carried out using SPSS version 25 (IBM Corp) and STATA
- version 15.0 (StataCorp LP).

2.5 Ethics and consent to participate

5 of 15

Vaccines 2020, 8, x FOR PEER REVIEW

The Ethics Committee of the National Institute for Infectious Diseases (Italian: Istituto Nazionale per le Malattie Infettive I.R.C.C.S. Lazzaro Spallanzani) approved the EPICOVID19 study protocol (Protocol No. 70, 12/4/2020). The participants were requested to give their informed consent when they first accessed the on-line platform. The study was carried out in accordance with the principles of the Declaration of Helsinki.

All data were handled and stored in accordance with the European Union General Data Protection Regulation (EU GDPR) 2016/679; data transfer included encrypting/decrypting and password protection.

3. Results

164

165

166

167

168

169

170

171

172

177

Between April and June 2020 198,822 participants filled the online EPICOVID 19 survey and 41,818 (21.0%) reported to have received a flu vaccination shot during the last influenza season (2019/2020). Respondents were prevalently females (59.7%) and aged between 18-64 years (85.9%) with a mean age of 48 (SD +/- 14.7 years) (Table 1).

Flu shot during 2019/2020 flu season

		Flu shot d	Flu shot during 2019/2020 flu season			
		No	No			
		N=157004	Yes	N=198822		
		(79.0)	N=41818 (21.0)	(100)		
Sex at birth	Females	95402 (80.4)	23255 (19.6)	118657 (59.7)		
	Males	61602 (76.8)	18563 (23.2)	80165 (40.3)		
Class of age	<65 years	143921 (84.3)	26809 (15.7)	170730 (85.9)		
	65+ years	13083 (46.6)	15009 (53.4)	28092 (14.1)		
Age		45.9 ± 13.6	55.8 ± 15.9	48.0 ± 14.7		
Educational level	Low	8662 (73.1)	3192 (26.9)	11854 (6.0)		
	Middle	56058 (81.5)	12742 (18.5)	68800 (34.6)		
	High	92284 (78.1)	25884 (21.9)	118168 (59.4)		
Employment status	Employed	114488 (83.7)	22368 (16.3)	136856 (68.8)		
	Student	11781 (87.7)	1655 (12.3)	13436 (6.8)		
	Unemployed	8064 (87.8)	1120 (12.2)	9184 (4.6)		
	Retired	14056 (49.7)	14252 (50.3)	28308 (14.2)		
	Other	8615 (78.0)	2423 (22.0)	11038 (5.6)		
Morbidities or clinical	Lung diseases	7497 (65.4)	3959 (34.6)	11456 (5.8)		
conditions	Heart disease	2996 (47.5)	3318 (52.5)	6314 (3.2)		
	Metabolic disorders	5662 (60.7)	3663 (39.3)	9325 (4.7)		
	Renal diseases	1044 (61.8)	644 (38.2)	1688 (0.8)		
	Oncological diseases	3809 (60.0)	2541 (40.0)	6350 (3.2)		
	Diseases of the immune system	12998 (74.2)	4516 (25.8)	17514 (8.8)		
	Liver diseases	999 (67.2)	488 (32.8)	1487 (0.7)		
	Surgical procedures	5499 (72.3)	2103 (27.7)	7602 (3.8)		
Number of morbidities	None	123240 (82.6)	25928 (17.4)	149168 (75.0)		
	One	28077 (70.6)	11689 (29.4)	39766 (20.0)		
	Two	4782 (59.2)	3297 (40.8)	8079 (4.1)		

Vaccines 2020 , 8, x FOR PE	ER REVIEW			6 of 15
	Three or more	905 (50.0)	904 (50.0)	1809 (0.9)
Work categories	Health professionals	9474 (64.3)	5262 (35.7)	14736 (7.4)
recommended for flu vaccine	Armed forces	1610 (79.8)	407 (20.2)	2017 (1.0)
	Agricultural, forestry and fishery workers	674 (82.3)	145 (17.7)	819 (0.4)
Other conditions for	Pregnancy	2446 (76.7)	743 (23.3)	3189 (1.6)
recommending flu vaccine	Residents in nursing home	129 (39.0)	202 (61.0)	331 (0.2)
	Cohabitants at risk	26883 (70.5)	11225 (29.5)	38108 (19.2)
	Not self-sufficient in carrying out daily activities	425 (46.0)	499 (54.0)	924 (0.5)
Self-perceived health status	Good	135325 (80.9)	31942 (19.1)	167267 (84.1)
	Adequate	20585 (69.2)	9159 (30.8)	29744 (15.0)
	Bad	1094 (60.4)	717 (39.6)	1811 (0.9)

Table 1: characteristics of study participants according to being or not vaccinated for influenza in the 2019/2020 flu season.

Vaccination coverage progressively increased with age, from 11% between 18 and 24 years of age and peaking to 72.9% between 85 and 89 years of age (Supplementary Table 1).

	Flu shot during 2019/2020 flu season			
	No	Yes	Total	
Class of age	N=157004 (79.0)	N=41818 (21.0)	N=198822 (100)	
18-24	8916 (89.0)	1099 (11.0)	10015 (5.0)	
25-29	12965 (87.6)	1839 (12.4)	14804 (7.4)	
30-34	15539 (87.1)	2311 (12.9)	17850 (9.0)	
35-39	17049 (85.6)	2864 (14.4)	19913 (10.0)	
40-44	17260 (85.0)	3036 (15.0)	20296 (10.2)	
45-49	19391 (86.4)	3055 (13.6)	22446 (11.3)	
50-54	19848 (86.0)	3235 (14.0)	23083 (11.6)	
55-59	18753 (81.7)	4195 (18.3)	22948 (11.5)	
60-64	14200 (73.3)	5175 (26.7)	19375 (9.7)	
65-69	7885 (55.3)	6373 (44.7)	14258 (7.2)	
70-74	3504 (41.1)	5018 (58.9)	8522 (4.3)	
75-79	1081 (35.1)	2003 (64.9)	3084 (1.6)	
80-84	379 (27.5)	998 (72.5)	1377 (0.7)	
85-89	136 (27.0)	367 (73.0)	503 (0.3)	
90+	98 (28.2)	250 (71.8)	348 (0.2)	

Supplementary Table 1. Vaccination coverage in participants according to the class of age.

183

180

181

182

7 of 15

Vaccines 2020, 8, x FOR PEER REVIEW


In particular, 15,009 (53.4%) subjects aged 65 years or older received a flu vaccination shot during the last influenza season. The comparison between vaccination covered per class of age and the official Italian from are reported in Supplementary Table 2.

		Flu shot rates by class of age		
	_	National 2109-2020	EPICOVID19	
Class of age	18-44 years	574,335/18,526,934 (3.1)	11,149/82,878 (13.5)	
	45-64 years	1,749,887/18,227,994 (9.6)	15,660/87,852 (17.8)	
	18-64 years	2,324,222/36,754,928 (6.3)	26,809/170,730 (15.7)	
	65+ years	7,615,037/13,946,954 (54.6)	15,009/28,092 (53.4)	
	60-64 years	-	5,175/19,375 (26.7)	

Supplementary Table 2. Vaccination coverage per class of age according to the Italian official national data and in the EPICOVID19 respondents.

More than half of the respondents (59.4%) had high educational level, whereas 34.6% and 6% reported medium and high educational level. More than seventy-five percent of respondents (149,168; 75%) reported no diseases, whereas the remaining 25% reported at least one clinical condition representing *per se* a flu vaccine indication. Vaccination coverage progressively increased up to 50.0% in those reporting 3 or more comorbidities. Among participants reporting at least one condition, those with heart disease showed the higher vaccination coverage (52.5%) followed by those reporting oncological diseases (40%) and metabolic disorders (39%); whereas only 34.6% of those with lung diseases reported to be vaccinated for influenza. Among the professions with an indication for flu vaccination, health care workers were those with the higher coverage (35.7%).

Vaccination coverage ranged widely across Italian regions, from 18.2% in Abruzzo to 23.7% in Friuli-Venezia Giulia in the overall respondents (Figure 1A) and from 48.7% in Piemonte to 63.6% Friuli-Venezia Giulia in those aged ≥ 65 years (Figure 1B).



Vaccines 2020, 8, x FOR PEER REVIEW

8 of 15

Figure 1. A, vaccination coverage according to the different Italian region in respondents aged \geq 18 years. B, vaccination coverage according to the different Italian regions in respondents aged \geq 65 years.

3.1 Multivariable model of factors associated to flu vaccination

Figure 2 shows the multivariable model for subjects aged 18 years or older.




Figure 2. Multivariable model of factors associated to flu vaccination in the 2019/2020 season in respondents aged \geq 18 years.

The multivariable model stratified by age (18-64 years and \geq 65 years) are reported in Table 2. When considering the whole respondents, being 65 years or older (aOR 3.06, 95%CI 2.92-3.20) and having a high education level (aOR 1.34. 95%CI 1.28-1.41) were independently associated to flu vaccination. Conversely, those unemployed showed a reduced odds of being vaccinated (aOR 0.80, 95%CI 0.75-0.85).

	Vaccines 2020, 8, x FOR PEER REVIEW
222	
223	
224	
225	
226	
227	

	Age 18-64 years		Age≥65 years	
	N=26.809/170.730 (15.7)	N=15.009/28.092	
	aOR (95%CI)	p	aOR (95%CI)	p
Sex and pregnancy				
Males	1		1	
Not pregnant females	0.83 (0.81 to 0.85)	.000	1.19 (1.13 to	.000
Pregnant females	1.68 (1.54 to 1.85)	.000	1.25)	.000
Age, per 10 years more	1.24 (1.22 to 1.26)	.000	2.01 (1.90 to	.000
Educational level				
Low	1		1	
Middle	1.08 (1.01 to 1.16)	.034	1.06 (0.98 to	.134
High	1.59 (1.49 to 1.71)	.000	1.40 (1.29 to	.000
Employment status				
Employed	1		1	
Student	1.50 (1.40 to 1.59)	.000	_	
Unemployed	0.88 (0.82 to 0.94)	.000	1.11 (0.80 to	.532
Retired	1.65 (1.54 to 1.76)	.000	1.52 (1.40 to	.000
Other	1.09 (1.02 to 1.15)	.006	1.24 (1.10 to	.001
Morbidities or clinical conditions				
Lung diseases	1.95 (1.85 to 2.05)	.000	1.91 (1.73 to	.000
Heart disease	2.15 (1.98 to 2.33)	.000	1.54 (1.42 to	.000
Metabolic disorders	1.68 (1.58 to 1.78)	.000	1.33 (1.23 to	.000
Renal diseases	1.41 (1.22 to 1.63)	.000	1.10 (0.91 to	.305
Oncological diseases	1.62 (1.50 to 1.75)	.000	1.16 (1.06 to	.001
Diseases of the immune system	1.17 (1.12 to 1.23)	.000	1.02 (0.94 to	.583
Liver diseases	1.00 (0.85 to 1.18)	.972	0.92 (0.76 to	.410
Surgical procedures	1.06 (0.99 to 1.14)	.093	1.13 (1.02 to	.021
Work categories recommended for flu vaccine				
Not recommended	1		1	
Agricultural, forestry and fishery workers	0.79 (0.62 to 1.00)	.047	0.97 (0.66 to	.895
Armed forces	0.97 (0.85 to 1.12)	.699	1.24 (0.93 to	.139
Health professionals	2.99 (2.87 to 3.11)	.000	1.54 (1.36 to	.000
Other conditions for recommending flu vaccine				
Residents in nursing home	7.20 (4.29 to 12.10)	.000	0.39 (0.28 to	.000
Presence of persons at risk in the household	1.36 (1.31 to 1.40)	.000	1.42 (1.35 to	.000
Not self-sufficient in carrying out daily activities	1.83 (1.41 to 2.38)	.000	0.54 (0.43 to	.000
Self-perceived health status	,		·	
Good	1		1	
Adequate	1.15 (1.10 to 1.19)	.000	1.16 (1.10 to	.000

Vaccines 2020, 8, x FOR PEER REVIEW

10 of 15

	Bad	1.24 (1.08 to 1.42)	.002	1.36 (1.12 to	.002
228	Table 2. Multivariable binary logistic regression a	analysis on the pro	babilit	y of being or	not
229	vaccinated during the 2019/2020 flu season accor	ding to being 18-64	years	old or ≥ 65 y	ears
230	old.				

Among comorbidities, heart and lung diseases were conditions associated with higher odds of being vaccinated, both in subjects aged 18-64 [aOR 2.15 (1.98 to 2.33) and aOR 1.95 (1.85 to 2.05), respectively] and in those aged above 65 years [aOR 1.54 (95%CI 1.42-1.67) and aOR 1.91 (95%CI 1.73-2.12), respectively]. The odds of being vaccinated progressively increased with the number of reported morbidities, with a more pronounced effect in those aged below 65 years (Supplementary Table 3).

	Age 18-64 years		Age≥65 years		
	N=26.809/170.730	N=26.809/170.730 (15.7)		(53.4)	
	aOR (95%CI)	aOR (95%CI) p aOR		p	
Number of morbidities					
None	1		1		
One	1.54 (1.49 to 1.59)	.000	1.43 (1.35 to 1.51)	.000	
Two	2.18 (2.05 to 2.33)	.000	1.70 (1.55 to 1.86)	.000	
Three or more	2.60 (2.26 to 2.99)	.000	1.66 (1.42 to 1.94)	.000	

Supplementary Table 3. Multivariable binary logistic regression analysis on the probability of being or not vaccinated during the 2019/2020 flu season according to the number of reported morbidities.

Health care workers showed a higher odds of being vaccinated [aOR 2.79 (95%CI 2.68-2.90)] when compared to work position without vaccine recommendation.

Living in a nursing home and being unable to perform daily activities were both associated with a lower odds of being vaccinated in those aged 65 years or older [aOR 0.39 (95%CI 0.28-0.54) and aOR 0.54 (95%CI 0.43-0.69), respectively].

4. Discussion

The EPICOVID 19 web based survey, which aimed to highlight different epidemiological and clinical aspects of COVID-19 epidemic in the first wave of the Italian epidemic, allowed the assessment of flu vaccination coverage in the 2019/2020 flu season in a large unselected sample of respondents. Moreover, we were able to identify predictors of flu vaccine uptake and highlight significant gaps in vaccination coverage in key populations such as in those residing in nursing homes and in those reporting specific medical conditions (i.e. liver diseases, kidney diseases and diseases of the immune system).

Our findings showed an overall vaccination rate of 21% and a rate of 53.4% in those aged 65 years or older, clearly below the target recommended coverage. The available National data obtained from a surveillance system collecting data from the general practitioners since 1990/2000 flu season, report a progressive increase in the vaccination coverage until 2009/2010 for the overall population (19.6 per 100 inhabitants) and until 2008/2009 for those aged 65 years or older (66.3 per 100 inhabitants). A progressive decline was subsequently observed for those aged 65 years or older until 2014/2015 (48.5 per 100 inhabitants) followed by a slight progressive increase in the subsequent years [17]. According to the official data of the Italian Ministry of Health of vaccination coverage in 2019/2020 flu season the overall vaccination coverage in the whole Italian population was 16.7 over 100 inhabitants and 54.6 over 100 inhabitants in those aged 65 years or older confirming the trend

Vaccines 2020, 8, x FOR PEER REVIEW

toward an increasing vaccination coverage [18]. Our data can not to be applied to the general estimates due to the absence in the survey of subjects aged 17 or younger. Whereas, the vaccination coverage observed in those aged 65 years or older appeared to be quite comparable to that reported by the official estimates (53.4% vs 54.6%, respectively). Although slightly increasing in recent years, the percentage observed in our study is lower than the target coverage of 75% in those aged 65 years or older. These data are particularly worrisome, because in the current fall/winter season in the northern hemisphere, with the concomitant co-circulation of both influenza and SARS-CoV-2 viruses, we will face a major challenge due to diagnostic and clinical problems in the presence of upper and lower respiratory tract symptoms [19]. Based on these concerns, for the 2020/2021 flu season the Italian ministry of Health recommends extending the vaccination coverage to the whole population, free of charge also for subject aged between 60 and 64 years [20]. If the free-of-charge administration of the influenza vaccine in this age-group will improve the uptake is to be

Recent findings support the need to increase the vaccination coverage, considering, on top of the well-known health and economic advantages, also the observed association between flu vaccination and reduction in SARS-CoV-2 nasopharyngeal swab positivity [15] and lower COVID-19 severity and mortality [21-23]. Therefore, the impact of vaccinations should be assessed not only based on their ability to prevent the related infections, but also on their broader impact on other communicable and not-communicable diseases occurring concurrently in the target population.

demonstrated, but it will help to quantify the impact of the economical barrier to vaccination.

Our findings highlight a worrisome low vaccination coverage in subjects aged between 60-64 years and 65-69 years (26.7% and 44.7%, respectively). The low vaccination coverage in this group could be partially explained by a self-perception of wellbeing and low risk perception [24]. Nevertheless, these age groups are at high risk of COVID-19 complications and mortality, as observed in the Italian COVID-19 patients, therefore strategies to overcome their hesitancy towards vaccines and to increase vaccine accessibility and uptake are of paramount relevance [4, 25].

Another interesting finding observed is that people with higher education level seems to be better predisposed to vaccination when compared to the low socio-economic level. If on the one hand, low education level is a known general barrier to vaccines [26] on the other, our sample of generally higher educational level compared to the general population, reported overall a low uptake, meaning that multiple factors, beyond health literacy and access to health care services, need to be addressed. Moreover, the finding of a higher coverage among those with comorbidities suggest an attitude to consider the vaccination as a relevant intervention mainly for individuals at high risk, and not as a meaningful intervention for health promotion [27].

Our results showed that patients with heart and lung diseases seem to have a higher odds of being vaccinated when compared to those with other comorbidities, in particular kidney and liver disease. These findings raise particular concern, because it is clearly demonstrated that patients with chronic conditions, not only cardiovascular or respiratory diseases, are at higher risk of many vaccine-preventable diseases, including influenza, that increase the risk of serious complications, hospitalization, and death. Moreover, vaccine preventable diseases are more difficult to manage, because of increased risk of drug interactions and potential adverse effects [27].

In our study, flu vaccination resulted positively associated with being a health care worker, compared to other work-categories. Nevertheless, an extremely low percentage of health care workers respondents accounting for 35.7% received a flu shot in the last season. Although the percentage reported in our study is surprisingly higher compared to that reported in the literature in Italian health care workers, ranging from 14% [28] to 16% [29], it underlines the need for urgent measures to increase vaccination coverage in Italian health care workers. Vaccination of health care workers against influenza is a key component of infection control, and the rationale for it is based on the need to protect the health care workers and their high-risk patients in nursing homes, hospitals,

Vaccines 2020, 8, x FOR PEER REVIEW

- 12 of 15
- 311 and outpatient clinics. Moreover, in time of extreme demand, reducing the absenteeism due to
- 312 influenza and its complications, contributes to the preservation of the essential health care services.
- 313 The finding that nursing home residents aged 65 years or older have a 61% higher odds of not being
- 314 vaccinated compared to the rest of the population was unexpected and definitively worrisome.
- 315 These subjects have high rates of underlying medical conditions and, therefore, are at higher risk of
- 316 infectious disease outbreaks. As we have learned during the recent pandemic, about half of deaths
- 317 due to COVID-19 were among nursing homes residents, underlying a critical health disparity that
- 318 need to be addressed urgently. Increased vaccination rates and increased testing for preventable
- 319 infectious disease of residents and staff, and increased access to personal protective measures and
- 320 equipment are mandatory in all nursing homes, in order to protect this vulnerable subgroup of our
- 321 population [30-32].

322

4.1 Strengths and limitations

- 323 The main strength of our research was the possibility to assess factors associated with flu vaccination
- 324 in a large unselected group of respondents to an online survey. In fact, Italian estimates on past flu
- 325 vaccination seasons reported aggregated data for the general population and for those aged 65 years
- 326 or older but failed to address among the target group which are categories with significant barriers
- 327 to achieve the pre-planned goal for flu vaccine coverage.
- 328 Our study has several limitations. First, the absence of subjects aged below 18 years makes
- 329 impossible the comparison of our data with that of the Italian general population reported by the
- 330 ministry of health. Second, the high percentage of high education and health care workers observed
- 331 in our sample should be considered in the interpretation of the results for the possible impact on
- 332 behaviours and opportunities toward a better health. Third, caution is warranted in the
- 333 interpretation of flu vaccination coverage of nursing home residents due to the possibility of 334
- recalling bias. In the end, the sample cannot be considered fully representative of the Italian 335
- demographic curve and consequently our findings could be not completely generalizable to the
- 336 Italian population.

337 5. Conclusions

- 338 Our data confirm a low vaccination coverage in the overall respondents to the online EPICOVID 19
- 339 survey and in particular, far below the national recommendations in target populations, such as
- 340 those 65 years or older, in subjects at high risk due to chronic conditions and in health care workers.
- 341 In the perspective of the next fall winter season, with the probable co-circulation of influenza and
- 342 SARS-CoV-2 in the norther hemisphere, the population will remain vulnerable to concurrent
- 343 epidemics. The morbidity and mortality impact will be directly related to the strength of the public
- 344 health response, which must be based on effective infection prevention tools currently available: the
- 345 non-pharmacologic interventions (i.e. social distance and face masks) and the widespread
- 346 implementation of influenza vaccination to fill the gap of missed vaccination opportunities reported
- 347 in the past flu seasons.
- 348 **Supplementary Materials**: The following are available online at www.mdpi.com/xxx/s1,
- 349 Supplementary Table 1. Vaccination coverage in participants according to the class of age.
- 350 Supplementary Table 2. Vaccination coverage per class of age according to the Italian official national data for
- 351 the 2019/2020 flu season and in the EPICOVID19 respondents.
- 352 Supplementary Table 3. Multivariable binary logistic regression analysis on the probability of being or not
- 353 vaccinated during the 2019/2020 flu season according to the number of reported morbidities.

Vaccines 2020, 8, x FOR PEER REVIEW

13 of 15

- 354 Author Contributions: Conceptualization, A.G., M.G., S.M., F.P., F.A.; Formal analysis, F.P., F.A; Methodology,
- 355 A.G, M.G., S.M., F.P. and F.A.; Project administration, F.A.; Supervision, M.G. and F.A.; Writing—original draft,
- 356 A.G., M.G., F.P., S.M. and F.A.; Writing—review & editing, S.M, M.N., C.T., R. A.I, G.P., G.B, M.D.B, A.S., M.T., 357
- C.M., M.A., F.P., F.A. The corresponding author, A.G., attests that all listed authors meet authorship criteria and
- 358 that no others meeting the criteria have been omitted. All authors have read and agreed to the published
- 359 version of the manuscript.
- 360 Funding: This research received no external funding
- 361 Acknowledgments: The EPICOVID19 Working Group: Fulvio Adorni (National Research Council, Institute of 362 Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Federica Prinelli (National Research 363 Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Fabrizio Bianchi 364 (National Research Council, Institute of Clinical Physiology, Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Andrea 365 Giacomelli (Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di 366 Milano, ASST Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Gabriele Pagani 367 (Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST 368 Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Dario Bernacchia (Infectious 369 Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST 370 Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Stefano Rusconi (Infectious Diseases 371 Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST Fatebenefratelli 372 Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy); Stefania Maggi (National Research Council, 373 Neuroscience Institute, Aging branch, Via Vincenzo Maria Gallucci 16, 35128 Padova, Italy); Caterina Trevisan 374 (University of Padova, Department of Medicine (DIMED) – Geriatric Unit, Via Giustiniani 2, 35128 Padova 375 (PD), Italy; National Research Council, Neuroscience Institute, Via Giustiniani 2, 35128 Padova (PD), Italy); 376 Marianna Noale (National Research Council, Neuroscience Institute, Aging branch, Via Vincenzo Maria 377 Gallucci 16, 35128 Padova, Italy); Sabrina Molinaro (National Research Council, Institute of Clinical Physiology, 378 Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Luca Bastiani (National Research Council, Institute of Clinical 379 Physiology, Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Loredana Fortunato (National Research Council, Institute 380 of Clinical Physiology, Via G. Moruzzi 1, 56124 Pisa (PI), Italy); Nithiya Jesuthasan (National Research Council, 381 Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Aleksandra Sojic (National 382 Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate (MI), Italy); Carla 383 Pettenati (National Research Council, Institute of Biomedical Technologies, Via Fratelli Cervi 93, 20090 Segrate 384 (MI), Italy); Marcello Tavio (Division of Infectious Diseases, Azienda Ospedaliero Universitaria Ospedali 385 Riuniti, Ancona, Italy); Massimo Andreoni (Infectious Diseases Clinic, Department of System Medicine, Tor 386 Vergata University of Rome, 00133 Rome, Italy); Claudio Mastroianni (Public Health and Infectious Disease 387 Department, "Sapienza" University, Rome, Italy); Raffaele Antonelli Incalzi (Unit of Geriatrics, Department of 388 Medicine, Biomedical Campus of Rome, via Alvaro del Portillo, 21, 00128 Rome, Italy); Massimo Galli 389 (Infectious Diseases Unit, Department of Biomedical and Clinical Sciences L.Sacco, Università di Milano, ASST 390 Fatebenefratelli Sacco, Milan, Italy Via G.B. Grassi 74, 20157 Milano, Italy).
- 391 Conflicts of Interest: The authors declare no conflict of interest.

392 References

- 393 http://www.who.int/influenza/gisrs_laboratory/en/accessed 23/09/2020
- 394 Lai PL, Panatto D, Ansaldi F et al. Burden of the 1999-2008 seasonal influenza epidemics in Italy: 395 comparison with the H1N1v (A/California/07/09) pandemic. Hum Vaccin. 2011 Jan-Feb;7 Suppl:217-25.
- 396 3. Zehender G, Lai A, Bergna A, et al. Genomic characterization and phylogenetic analysis of SARS-COV-2 in 397 Italy [published online ahead of print, 2020 Mar 29]. J Med Virol. 2020;10.1002/jmv.25794.
- 398 Giacomelli A, Ridolfo AL, Milazzo L, et al. 30-day mortality in patients hospitalized with COVID-19 399 during the first wave of the Italian epidemic: A prospective cohort study. Pharmacol Res. 2020;158:104931.
- 400 Grasselli G, Zangrillo A, Zanella A, et al; COVID-19 Lombardy ICU Network. Baseline Characteristics and 401 Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. 402 JAMA. 2020 Apr 28;323(16):1574-1581.

Vaccines 2020, 8, x FOR PEER REVIEW

- 403 6. https://www.epicentro.iss.it/en/coronavirus/sars-cov-2-dashboard accessed 23/09/2020
- 404 7. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. *BMJ*. 2020;370:m2980. Published 2020 Jul 30. doi:10.1136/bmj.m2980
- 406 8. Bar-Zeev N, Inglesby T. COVID-19 vaccines: early success and remaining challenges. Lancet. 2020 Sep 3:S0140-6736(20)31867-5. doi: 10.1016/S0140-6736(20)31867-5.
- Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly. *Cochrane Database Syst Rev.* 2018;2(2):CD004876.
- 410 10. Jefferson T, Rivetti A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy
 411 children. *Cochrane Database Syst Rev.* 2018;2(2):CD004879. Published 2018 Feb 1.
 412 doi:10.1002/14651858.CD004879.pub5
- 413 11. Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. *Cochrane Database Syst Rev.* 2018;2(2):CD001269.
- Demurtas J, Celotto S, Beaudart C, et al. The efficacy and safety of influenza vaccination in older people:
 An umbrella review of evidence from meta-analyses of both observational and randomized controlled
 studies. Ageing Res Rev. 2020;62:101118.
- 418 13. Bonanni P, Boccalini S, Zanobini P, et al. The appropriateness of the use of influenza vaccines: 419 Recommendations from the latest seasons in Italy. Hum Vaccin Immunother. 2018 Mar 4;14(3):699-705.
- 420 14. Adorni F, Prinelli F, Bianchi F, et al. Self-reported symptoms of SARS-CoV-2 infection in a 421 non-hospitalized population: results from the large Italian web-based EPICOVID19 cross-sectional survey 422 [published online ahead of print, 2020 Jul 10]. *JMIR Public Health Surveill*. 2020;10.2196/21866.
- 423 15. Noale M, Trevisan C, Maggi S, et al. The Association between Influenza and Pneumococcal Vaccinations
 424 and SARS-Cov-2 Infection: Data from the EPICOVID19 Web-Based Survey. *Vaccines (Basel)*.
 425 2020;8(3):E471.
- 426 16. http://www.salute.gov.it/imgs/C 17 pubblicazioni 2571 allegato.pdf accessed 23/09/2020
- 427 17. http://www.salute.gov.it/portale/influenza/dettaglioContenutiInfluenza.jsp?lingua=italiano&id=679&area
 428 = influenza&menu=vuoto accessed 23/09/2020
- 429 18. https://www.epicentro.iss.it/vaccini/dati_Ita#flu_accessed 23/09/2020
- 430 19. Solomon DA, Sherman AC, Kanjilal S. Influenza in the COVID-19 Era. *JAMA*. Published online August 14,
 431 2020. doi:10.1001/jama.2020.14661
- 432 20. https://www.trovanorme.salute.gov.it/norme/renderNormsanPdf?anno=2020&codLeg=74451&parte=1%2
 433 0&serie=null Accessed 23/9/2020
- Zanettini C, Omar M, Dinalankara W, et al. Influenza Vaccination and COVID19 Mortality in the USA.
 Preprint. *medRxiv*. 2020;2020.06.24.20129817. Published 2020 Jun 26. doi:10.1101/2020.06.24.20129817
- 436 22. Fink, G.; Orlova-Fink, N.; Schindler, T.; Grisi, S.; Ferrer, A.P.; Daubenberger, C.; Brentani, A. Inactivated trivalent influenza vaccine is associated with lower mortality among Covid-19 patients in Brazil. *medRxiv* 2020.06.29.20142505; *doi: https://doi.org/10.1101/2020.06.29.20142505*
- 439 23. Amato M, Werba JP, Frigerio B, et al. Relationship between Influenza Vaccination Coverage Rate and COVID-19 Outbreak: An Italian Ecological Study. Vaccines (Basel). 2020;8(3):E535.

15 of 15

Vaccines 2020, 8, x FOR PEER REVIEW

24. Schmid P, Rauber D, Betsch C, Lidolt G, Denker ML. Barriers of Influenza Vaccination Intention and 442 Behavior - A Systematic Review of Influenza Vaccine Hesitancy, 2005 - 2016. PLoS One. 2017;12(1):e0170550. Published 2017 Jan 26. doi:10.1371/journal.pone.0170550

- 444 Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to 445 COVID-19 in Italy. JAMA. 2020;323(18):1775–1776. doi:10.1001/jama.2020.4683
- 446 Larson HJ, Jarrett C, Eckersberger E, Smith DM, Paterson P. Understanding vaccine hesitancy around 447 vaccines and vaccination from a global perspective: a systematic review of published literature, 448 2007-2012. Vaccine. 2014;32(19):2150-2159.
- 449 27. Doherty TM, Del Giudice G, Maggi S. Adult vaccination as part of a healthy lifestyle: moving from 450 medical intervention to health promotion. Ann Med. 2019;51(2):128-140.
- 451 Genovese C, Picerno IAM, Trimarchi G, et al. Vaccination coverage in healthcare workers: a multicenter 452 cross-sectional study in Italy. *J Prev Med Hyg.* 2019;60(1):E12-E17.
- 453 Alicino C, Iudici R, Barberis I, et al. Influenza vaccination among healthcare workers in 454 Italy. Hum Vaccin Immunother 2015;11(1):95-100.
- 455 Abrams HR, Loomer L, Gandhi A, Grabowski DC. Characteristics of U.S. Nursing Homes with COVID-19 456 Cases. J Am Geriatr Soc. 2020 Aug;68(8):1653-1656.
- 457 Roxby AC, Greninger AL, Hatfield KM, et al. Outbreak Investigation of COVID-19 Among Residents and 458 Staff of an Independent and Assisted Living Community for Older Adults in Seattle, Washington. JAMA 459 Intern Med. 2020;180(8):1101-1105.
- 460 Nanda A, Vura NVRK, Gravenstein S. COVID-19 in older adults. Aging Clin Exp Res. 2020 461 Jul;32(7):1199-1202. doi: 10.1007/s40520-020-01581-5. Epub 2020 May 10. PMID: 32390064; PMCID: 462 PMC7211267

441

443

